This site is intended for US healthcare professionals

Congresses

The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

POSTER
Safety and Pharmacodynamic Effects of the Orexin 2 Receptor Agonist ALKS 2680 in Patients With Narcolepsy Type 1: A First-in-Human Phase 1 Study
Author(s):

Ron Grunstein,1 Brendon Yee,1 Julia Chapman,1 Angela D’Rozario,1 Craig Hopkinson,2 Jandira Ramos,2 Daniel Smith,2 Sergey Yagoda,2 Bhaskar Rege2

1Woolcock Institute of Medical Research, Sydney, Australia; 2Alkermes, Inc., Waltham, Massachusetts

Content available until 06/01/2026